Earnings guidance provided by CVS management aligns with analyst price targets, creating consensus support for a steady upward trajectory in the CVS stock forecast However, the company still reported a 2.60% year-over-year revenue improvement in FQ2 2024. The revenue was $91.23 billion, while the earnings per share were $1.83. Investors are still expecting returns as we see that 60 hedge funds are long it. The highest stake is at $764,023,075 by Pzena Investment Management . Multiple analysts have issued price targets for $CVS recently. We have seen 11 analysts offer price targets for $CVS in the last 6 months, with a median target of $80.0. From a technical perspective, CVS’s chart patterns suggest a potential breakout by mid‑2025 if the $88 resistance level is breached, supporting a bullish CVS stock forecast